Table 2. Results of second-line treatments for progestin-insensitive patients (n=57).

Initial treatments	Second-line treatments	No.	Treatment duration to achieve CR* (wk) (median, range)	28-week cumulative CR* rate, %	Remained PR* after 28 weeks of second-line treatment, % (No.)	Remained SD* after 28 weeks of second-line treatment, % (No.)	28-week cumulative PD* rate, %
MA/MPA	Prolonged treatment duration†	7	12 (8–32)	71.4	14.3 (1/7)	14.3 (1/7)	0.0
MA/MPA + metformin	Prolonged treatment duration†	5	20 (12–28)	100.0	0.0 (0/5)	0.0 (0/5)	0.0
MA/MPA	MA + metformin	12	23 (9–100)	66.7	25.0 (3/12)	8.3 (1/12)	0.0
MA/MPA ± metformin	Ethinylestradiol cyproterone + metformin	26	19 (6–41)	83.2	11.5 (3/26)	3.8 (1/26)	7.7
MA/MPA ± metformin	MA + LNG-IUS ± metformin	7	27 (12–56)	57.1	42.9 (3/7)	0.0 (0/7)	0.0

Treatment duration is shown as median (range).

^*Treatment duration for these progestin insensitive patients was defined as from the time point of initiating second line treatment to the time point indicated in each column. ^†Kept on original treatment.

CR, complete response; LNG-IUS, levonorgestrel-releasing intrauterine system; MA, megestrol acetate; MPA, medroxyprogesterone acetate; PD, progressed disease; PR, partial response; SD, stable disease.